Organization (Academic)
East Tennessee State University
ClinicalTrials.gov lists East Tennessee State University as lead sponsor of 21 trials. It has 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo East Tennessee State University, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers East Tennessee State University: 21 lead-sponsored trials and 1 legal-entity registration.
Disease areas (35)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Dementia | 2 |
| Substance-Related Disorders | 2 |
| Waterborne Diseases | 2 |
Showing 5 of 35 disease areas.
Trials by start year as sponsor or collaborator (16)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2023 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 4 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 1 |
Showing 10 of 16 years.
Recruitment duration, a model prediction: none of the 21 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Quetiapine | 1 |
| PIOGLITAZONE | 1 |
| Bupropion | 1 |
| Erythromycin | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 4 hit target (n=4) | 0 of 4 on time (n=4) |
Journals published in (34)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Biochimica et biophysica acta | 2 |
| The Journal of clinical endocrinology and metabolism | 2 |
| Acta neurologica Belgica | 1 |
| American journal of physiology. Endocrinology and metabolism | 1 |
| BMC bioinformatics | 1 |
Showing 5 of 34 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 23 | 3 | 2024-12-03 |
Financing and grant events (104)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-23 | NIH grant | 249,000 | Reporter |
| 2025-09-22 | NIH grant | 416,750 | Reporter |
| 2025-09-19 | NIH grant | 249,000 | Reporter |
| 2025-08-31 | NIH grant | 142,100 | Reporter |
| 2025-08-01 | NIH grant | 457,701 | Reporter |
Showing 5 of 104 events.
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| The University of Tennessee, Knoxville | Co sponsors trial with | 1 |
Latest dated events (154)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-23 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-22 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-09-19 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 154 events.
CLIA clinical laboratory certificates (3)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| EAST TENNESSEE STATE UNIVERSITY | Certificate for PPM procedures | Active |
| EAST TENNESSEE STATE UNIVERSITY | Certificate for PPM procedures | Active |
| EAST TENNESSEE STATE UNIVERSITY, | Certificate for PPM procedures | Terminated |
Biomarkers this organization publishes on (282)
Shown in this order: most publications first.
Showing 5 of 282 biomarkers.
On Scientist.com
East Tennessee State University is linked to 3 research suppliers in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and biomarker capability evidence.
Work with East Tennessee State University College of Medicine Molecular Biology Core Facility on Scientist.com
For prices, more details, or to contact East Tennessee State University College of Medicine Molecular Biology Core Facility, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.